News articles
GET {{baseUrl}}/v1beta1/news
Returns latest news articles across stocks and crypto. By default returns latest 10 news articles.
Request Params
| Key | Datatype | Required | Description |
|---|---|---|---|
start | string | The inclusive start of the interval. Format: RFC-3339 or YYYY-MM-DD. | |
| If missing, the default value is the beginning of the current day. | |||
end | string | The inclusive end of the interval. Format: RFC-3339 or YYYY-MM-DD. | |
| If missing, the default value is the current time. | |||
sort | string | Sort articles by updated date. | |
symbols | string | The comma-separated list of symbols to query news for. | |
limit | number | Limit of news items to be returned for given page. | |
include_content | boolean | Boolean indicator to include content for news articles (if available) | |
exclude_contentless | boolean | Boolean indicator to exclude news articles that do not contain content | |
page_token | string | Pagination token to continue from. The value to pass here is returned in specific requests when more data is available than the request limit allows. |
HEADERS
| Key | Datatype | Required | Description |
|---|---|---|---|
Accept | string |
RESPONSES
status: OK
{"news":[{"author":"Vandana Singh","content":"","created_at":"2024-03-22T14:51:45Z","headline":"Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Higher On Friday?","id":37893076,"images":[{"size":"large","url":"https://cdn.benzinga.com/files/imagecache/2048x1536xUP/images/story/2024/Eyes_4.jpeg"},{"size":"small","url":"https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2024/Eyes_4.jpeg"},{"size":"thumb","url":"https://cdn.benzinga.com/files/imagecache/250x187xUP/images/story/2024/Eyes_4.jpeg"}],"source":"benzinga","summary":"Outlook Therapeutics stock sees uptick as European Medicines Agency committee issues positive opinion on ONS-5010/LYTENAVA for wet age-related macular degeneration (wet AMD). Strong trading volume reflects investor optimism. Potential for market exclusivity in EU.","symbols":["OTLK"],"updated_at":"2024-03-22T14:51:46Z","url":"https://www.benzinga.com/general/biotech/24/03/37893076/why-is-eye-disease-focused-outlook-therapeutics-stock-trading-higher-on-friday"},{"author":"Benzinga Newsdesk","content":"","created_at":"2024-03-22T14:48:18Z","headline":"RBC Capital Reiterates Outperform on Pyxis Oncology, Maintains $7 Price Target","id":37892990,"images":[],"source":"benzinga","summary":"","symbols":["PYXS"],"updated_at":"2024-03-22T14:48:19Z","url":"https://www.benzinga.com/news/24/03/37892990/rbc-capital-reiterates-outperform-on-pyxis-oncology-maintains-7-price-target"},{"author":"Benzinga Newsdesk","content":"","created_at":"2024-03-22T14:45:40Z","headline":"RBC Capital Reiterates Sector Perform on FactSet Research Systems, Maintains $464 Price Target","id":37892941,"images":[],"source":"benzinga","summary":"","symbols":["FDS"],"updated_at":"2024-03-22T14:45:41Z","url":"https://www.benzinga.com/news/24/03/37892941/rbc-capital-reiterates-sector-perform-on-factset-research-systems-maintains-464-price-target"},{"author":"Chris Katje","content":"","created_at":"2024-03-22T14:44:26Z","headline":"Nike Stock Falls On Guidance, Turnaround Plan: Analysts See 'Buying Opportunity,' But Caution 'These Strategies Will Take Time'","id":37892915,"images":[{"size":"large","url":"https://cdn.benzinga.com/files/imagecache/2048x1536xUP/images/story/2024/nike-shutter.jpeg"},{"size":"small","url":"https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2024/nike-shutter.jpeg"},{"size":"thumb","url":"https://cdn.benzinga.com/files/imagecache/250x187xUP/images/story/2024/nike-shutter.jpeg"}],"source":"benzinga","summary":"Nike stock is trading lower after third quarter results. The company reported guidance that was weaker than expected. Analysts size up what this means.","symbols":["NKE"],"updated_at":"2024-03-22T14:44:27Z","url":"https://www.benzinga.com/24/03/37892915/nike-stock-falls-on-guidance-turnaround-plan-analysts-see-buying-opportunity-but-caution-these-strat"},{"author":"Benzinga Newsdesk","content":"","created_at":"2024-03-22T14:42:12Z","headline":"RBC Capital Maintains Outperform on Accenture, Raises Price Target to $381","id":37892858,"images":[],"source":"benzinga","summary":"","symbols":["ACN"],"updated_at":"2024-03-22T14:42:13Z","url":"https://www.benzinga.com/news/24/03/37892858/rbc-capital-maintains-outperform-on-accenture-raises-price-target-to-381"},{"author":"Benzinga Newsdesk","content":"","created_at":"2024-03-22T14:41:36Z","headline":"Mizuho Maintains Underperform on Delek US Hldgs, Raises Price Target to $30","id":37892838,"images":[],"source":"benzinga","summary":"","symbols":["DK"],"updated_at":"2024-03-22T14:41:36Z","url":"https://www.benzinga.com/news/24/03/37892838/mizuho-maintains-underperform-on-delek-us-hldgs-raises-price-target-to-30"},{"author":"Anusuya Lahiri","content":"","created_at":"2024-03-22T14:41:14Z","headline":"Apple Wants to Strengthen Presence in China, In Talks With Baidu Over AI Collaboration","id":37892837,"images":[{"size":"large","url":"https://cdn.benzinga.com/files/imagecache/2048x1536xUP/images/story/2024/Apple-Vision-Pro_54.jpeg"},{"size":"small","url":"https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2024/Apple-Vision-Pro_54.jpeg"},{"size":"thumb","url":"https://cdn.benzinga.com/files/imagecache/250x187xUP/images/story/2024/Apple-Vision-Pro_54.jpeg"}],"source":"benzinga","summary":"Apple is in talks with Baidu to incorporate their AI technology into devices in China, aligning with regulations. This could impact US chip suppliers.","symbols":["AAPL","BIDU","GOOG","GOOGL","NVDA"],"updated_at":"2024-03-22T14:41:15Z","url":"https://www.benzinga.com/government/24/03/37892837/apple-wants-to-strengthen-presence-in-china-in-talks-with-baidu-over-ai-collaboration"},{"author":"Benzinga Newsdesk","content":"","created_at":"2024-03-22T14:39:16Z","headline":"Mizuho Maintains Neutral on HF Sinclair, Raises Price Target to $66","id":37892764,"images":[],"source":"benzinga","summary":"","symbols":["DINO"],"updated_at":"2024-03-22T14:39:17Z","url":"https://www.benzinga.com/news/24/03/37892764/mizuho-maintains-neutral-on-hf-sinclair-raises-price-target-to-66"},{"author":"Benzinga Newsdesk","content":"","created_at":"2024-03-22T14:38:44Z","headline":"RBC Capital Reiterates Outperform on AAR, Maintains $80 Price Target","id":37892746,"images":[],"source":"benzinga","summary":"","symbols":["AIR"],"updated_at":"2024-03-22T14:38:45Z","url":"https://www.benzinga.com/news/24/03/37892746/rbc-capital-reiterates-outperform-on-aar-maintains-80-price-target"},{"author":"Vandana Singh","content":"","created_at":"2024-03-22T14:37:35Z","headline":"Why Is Fungal Infections-Focused Matinas BioPharma Stock Trading Higher On Friday?","id":37892736,"images":[{"size":"large","url":"https://cdn.benzinga.com/files/imagecache/2048x1536xUP/images/story/2024/Labs_1.jpeg"},{"size":"small","url":"https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2024/Labs_1.jpeg"},{"size":"thumb","url":"https://cdn.benzinga.com/files/imagecache/250x187xUP/images/story/2024/Labs_1.jpeg"}],"source":"benzinga","summary":"Progress with Matinas BioPharma\u0026#39;s MAT2203 for invasive fusarium infection. Clinical response achieved in patients resistant to other antifungals.","symbols":["MTNB"],"updated_at":"2024-03-22T14:37:36Z","url":"https://www.benzinga.com/general/biotech/24/03/37892736/why-is-fungal-infections-focused-matinas-biopharma-stock-trading-higher-on-friday"}],"next_page_token":"MTcxMTExODI1NjAwMDAwMDAwMHwzNzg5MjczNg=="}